

## Requirement of the *Yersinia pseudotuberculosis* Effectors YopH and YopE in Colonization and Persistence in Intestinal and Lymph Tissues

Lauren K. Logsdon\* and Joan Mecsas\*

Department of Microbiology and Molecular Biology, Tufts University, Boston, Massachusetts 02111

Received 13 March 2003/Returned for modification 1 May 2003/Accepted 27 May 2003

**The gram-negative enteric pathogen *Yersinia pseudotuberculosis* employs a type III secretion system and effector Yop proteins that are required for virulence. Mutations in the type III secretion-translocation apparatus have been shown to cause defects in colonization of the murine cecum, suggesting roles for one or more effector Yops in the intestinal tract. To investigate this possibility, isogenic *yop* mutant strains were tested for their ability to colonize and persist in intestinal and associated lymph tissues of the mouse following orogastric inoculation. In single-strain infections, a *yopHEMOJ* mutant strain was unable to colonize, replicate, or persist in intestinal and lymph tissues. A *yopH* mutant strain specifically fails to colonize the mesenteric lymph nodes, but *yopE* and *yopO* mutant strains showed only minor defects in persistence in intestinal and lymph tissues. While no single Yop was found to be essential for colonization or persistence in intestinal tissues in single-strain infections, the absence of both YopH and YopE together almost eliminated colonization of all tissues, indicating either that these two Yops have some redundant functions or that *Y. pseudotuberculosis* employs multiple strategies for colonization. In competition infections with wild-type *Y. pseudotuberculosis*, the presence of wild-type bacteria severely hindered the ability of the *yopH*, *yopE*, and *yopO* mutants to persist in many tissues, suggesting that the wild-type bacteria either fills colonization niches or elicits host responses that the *yop* mutants are unable to withstand.**

*Yersinia pseudotuberculosis* is a gram-negative enteric pathogen that causes gastroenteritis and mesenteric lymphadenitis and can spread systemically in humans and other mammals (31, 49, 60). Infection with *Y. pseudotuberculosis* usually occurs by ingestion of contaminated food (predominantly pork and milk products) or water (6, 11, 31, 49). Early after oral inoculation of a mouse, *Y. pseudotuberculosis* is found in the intestines, the lymph follicles called Peyer's patches (PP) that line the small intestine, and the mesenteric lymph nodes (MLN). In general, the bacteria are found extracellularly (63), but the bacteria reach the PP by binding, invading, and traversing through specialized M cells that overlay the PP (3, 13, 38). Late in infection (3 to 5 days postinfection), bacteria can be isolated from the spleen and liver in infection that usually leads to fatality in mice.

All three pathogenic *Yersinia* species, the enteric pathogens *Y. pseudotuberculosis* and *Y. enterocolitica* and the causative agent of plague, *Y. pestis*, share a tropism for lymph tissues and a 70-kb virulence plasmid called pYV that is essential for virulence (24, 52, 53). The pYV plasmid encodes a type III secretion system and effector proteins called Yops. The type III secretion system functions to secrete Yops from the bacterial cytoplasm and translocate them into mammalian cells, where they interact with specific host targets, altering host cell function. YopB and YopD are essential for translocation of the effector Yops into mammalian cells but not for secretion of effector Yops into the extracellular milieu (28, 48, 70).

In general, *Yersinia* Yops are thought to modulate the host

immune defenses and allow bacteria to replicate extracellularly in lymph tissues and organs (14, 63). At least six effector Yops have been identified in *Yersinia*: YopH, YopE, YopM, YopO (YpkA), YopJ (YopP in *Y. enterocolitica*), and YopT. Biochemical activities, host protein targets, and effects on cultured cells have been described for most Yops. For instance, YopH, YopE, YopO, and YopT play roles in preventing phagocytosis of the bacteria by macrophages, neutrophils, and/or epithelial cells; however, the deletion of any one of these Yops does not eliminate the antiphagocytic activity of the bacteria (1, 2, 5, 18, 26, 55–57). YopE and YopT cause cytotoxicity of epithelial cells (5, 32). Finally, YopJ induces apoptosis of macrophages (43, 45, 59). YopH is a tyrosine phosphatase (9, 27) which targets many proteins, leading to a variety of different effects in cultured cells. YopH localizes to focal adhesions and affects integrin signaling, thereby preventing phagocytosis (1, 2, 18, 50, 51, 55). YopH also affects the oxidative burst of macrophages (7) and inhibits T- and B-cell signaling (71), T-cell proliferation (61), and Ca<sup>2+</sup> signaling in neutrophils (2). YopE is a Rho/Rac GTPase-activating protein (GAP) that destabilizes actin filaments and thereby prevents phagocytosis (5, 26, 56, 58, 69). YopT inactivates RhoA (74); however, YopT is not produced in all *Y. pseudotuberculosis* strains, including the one used in the study described here (51). YopO affects the actin cytoskeleton of epithelial cells (16, 28, 34) and binds to Rho and Rac in either the GTP- or GDP-bound state (4, 28). However, the cellular targets of YopO and its exact mechanism and function in virulence are still unknown. YopM is the only Yop that localizes to the nucleus of eukaryotic cells after translocation (35, 64) and was recently found to interact with two mammalian kinases, PRK2 and RSK1 (39).

Mutations in most of the Yops of *Yersinia* spp. attenuate virulence in animal infections. In most cases, the roles of the

\* Corresponding authors. Mailing address: Department of Microbiology and Molecular Biology, Tufts University, 136 Harrison Ave., Boston, MA 02111. Phone: (617) 636-2742. Fax: (617) 636-0337. E-mail for J. Mecsas: joan.mecsas@tufts.edu. E-mail for L. K. Logsdon: lauren.logsdon@tufts.edu.

Yops in virulence were identified by assaying for the ability of the *yop* mutant strain to cause death of infected mice. Such experiments identified YopH, YopE, YopO, YopJ, and YopM as virulence factors (9, 10, 19, 23, 36, 44, 46). Other studies have analyzed the ability of *yop* mutants to colonize specific tissues after oral infection. Following oral infection, *yopE* and *yopO* mutant strains colonize the PP early in infection but the mutants fail to survive to day 4 or colonize the spleen (5, 22, 23, 30, 65). Additionally, a *yopJ* mutant shows decreased colonization of the spleen and MLN at 4 days after oral infection (44). However, the considerable variation in how the animal experiments were conducted (i.e., different strains of inbred mice, different *Yersinia* species, and different routes of infection) makes it difficult to compare the relative importance of each Yop for colonization and persistence of the bacteria in various tissues.

A role for the Yops in the gastrointestinal (GI) tissues was revealed by a previous signature-tagged mutagenesis study (40). Mutants with defects in the plasmid-encoded type III secretion system (*ysc*) were outcompeted by wild-type bacteria for colonization of the cecum. However, these results did not indicate which, if any, of the known effector Yops are important for survival in the GI tract. It is conceivable that the type III secretion apparatus also transports other factors or has some role in addition to that of protein translocation. In this study, we have used a set of isogenic *yop* mutant strains in two types of mouse infections with BALB/c mice to determine the importance of YopE, YopH, YopO, and YopB in the colonization of the GI tract and lymph tissues and in causing weight loss and other signs of disease. Using single *yop* mutant strains, we determined that YopH is crucial for colonization of the MLN and that YopE and YopO play more modest roles in persistence in the ileum and PP. Using multiple-*yop* mutant strains, we found that YopH and YopE play essential roles in survival within the GI tract and lymph tissues within 48 h after infection. Additionally, we analyzed the effects of changes in dosage and the presence of wild-type bacteria on the ability of *yop* mutants to colonize, replicate, and persist.

#### MATERIALS AND METHODS

**Bacterial strains.** *Escherichia coli* SM10  $\lambda$ pir and SY327  $\lambda$ pir were grown in L (10 g of tryptone peptone, 5 g of yeast extract, and 5 g of NaCl per liter) broth or plates at 37°C. *Y. pseudotuberculosis* strains were grown in L or Luria-Bertani broth (10 g of tryptone peptone, 5 g of yeast extract, and 10 g of NaCl per liter) or on L plates at 26°C. Two wild-type *Y. pseudotuberculosis* strains were used in this work: one unmarked mouse-passaged strain (YPIII pIB1) and an isogenic kanamycin-resistant (Kan<sup>r</sup>) strain that carries a kanamycin marker in a neutral site on the chromosome with homology to *tonB* (40). The Kan<sup>r</sup> strain is as virulent as its unmarked parent in single-strain and competition infections (data not shown and see Fig. 4).

**Bacterial mutants.** Isogenic, unmarked *yop* deletions were constructed by deleting the majority of the coding region of each *yop* protein. The *yopE* deletion eliminated the *yopE* and *ycE* promoters and the first 175 residues of the YopE protein. The *yopH* deletion has previously been described (71). *yopB* and *yopO* are both carried in polycistronic operons; therefore, in-frame deletions of the coding regions were constructed. For these deletions, the initial 18 residues for *yopB* and 20 residues for *yopO* and the last 55 residues for *yopB* and 20 residues for *yopO* were not deleted to ensure expression of the downstream genes (*yopD* and *yopJ*, respectively). The *yop* deletions were constructed using the suicide vector pCVD442 by allelic exchange (15). Fragments containing 250 to 500 bp of flanking regions on each side of the deletion were constructed by PCR with primer pair 1 and 2 and primer pair 3 and 4 (Table 1) and were cloned into pCVD442 by using *SalI*, *SphI*, and *SacI* for the *yopB* and *yopO* strains and *SalI*, *SacI*, and *SphI* for the *yopE* strain. Plasmids were originally isolated in *E. coli*

TABLE 1. Primers used to construct *yop* deletions

Primer	Sequence
YopE 1	.....GCACATGTGCGACGAGCGTTGTATCTAATCCTG
YopE 2	.....CGTCAGGAGCTCAGCATCCTGTCCGGCAAATA
YopE 3	.....ACTGACGAGCTCGTATTCCCTTCTCGCAGTGG
YopE 4	.....CTGATGCCCGGGCCGATCGCTGCATCAATCCATAG
YopO 1	.....TCATGCGTCGACTCACATCCATCCCGCTC
YopO 2	.....GACGATGCATGCCACATAAGCACCTGGAAACGC
YopO 3	.....CGTTACGCATGCAAGATTAGGATGTTGCCCCG
YopO 4	.....CTGATGAGCTCGAGCGCATCAGCCAACATTGG
YopB 1	.....CTATGCGTCGACTACGAGGATGCTCACAAGGTC
YopB 2	.....AGCTGCGCATGCAGGCGCTGGTGTCTCGAC
YopB 3	.....GTACGTGCATGCAAGGCAGACATGGCAGCG
YopB 4	.....ATCTGCGAGCTCTTCTCGCTTTACGTCCAG
YopM 1	.....GTACCGTCGACTCAGCAGTAATACATTGGAC
YopM 2	.....AGCGTGCATGCGACTGTAGATACATTTCTTGGATTTATG
YopM 3	.....CAGTCGCATGCACGCTTTTGGAGTAGTACGCAAGAG
YopM 4	.....GATCCGAGCTCTGGTTCGTCAGAAAAACG

SY327, introduced into *E. coli* SM10  $\lambda$ pir, and then introduced into *Y. pseudotuberculosis* YPIII pYV (pIB1) by conjugation, as previously described (41).

To confirm loss of the cloning vector and normal maintenance of the pIB1 virulence plasmid, colonies were tested for resistance to ampicillin and irgasan and for their phenotypes on plates containing Congo red. *Yersinia* strains are naturally resistant to irgasan, while *E. coli* is sensitive to the antibiotic. The loss of the pYV virulence plasmid results in white colonies on L plates containing 0.005% Congo red, 20 mM sodium oxalate, and 20 mM magnesium chloride (54). Colonies that were Amp<sup>s</sup>, Irg<sup>r</sup>, and red on plates containing Congo red were analyzed by PCR and Southern blotting to determine whether they had acquired the appropriate deletions. Yop secretion was tested using type III secretion-inducing conditions by growing strains in low-Ca<sup>2+</sup> medium containing the Ca<sup>2+</sup> chelator sodium oxalate (20 mM) and MgCl<sub>2</sub> (20 mM) for 2 h at 26°C followed by 2 h at 37°C, by trichloroacetic acid precipitation of the supernatants and by analysis of secreted proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (19). Additionally, the deletion strains were tested for growth defects at both 26 and 37°C in L broth, low-Ca<sup>2+</sup> medium (20 mM Na oxalate, 20 mM MgCl<sub>2</sub>), and high-Ca<sup>2+</sup> medium (5 mM CaCl<sub>2</sub>) and were found to behave similarly to the wild-type strain.

Strains were further analyzed in cell culture assays, including assays for bacterial uptake (gentamicin protection assay), host cell cytotoxicity, and tyrosine phosphatase activity that have been previously described (41, 45, 73), to verify that mutant strains behaved as expected. For instance, the *yopH* mutant strain does not produce YopH, and thus, HeLa cells infected with the *yopH* strain do not exhibit elevated tyrosine phosphatase activity; however, the strain still produces all other Yops and thus behaves like the wild-type strain in assays for other Yop activities. The deleted *yopH* was replaced with a wild-type copy of *yopH*. This rescued strain was able to compete with wild-type *Y. pseudotuberculosis* in competition experiments (data not shown and see Fig. 6).

The multiple-*yop* mutant strains were constructed by allelic exchange using the appropriate pCVD442 deletion constructs and sequentially adding additional mutations to the *Yersinia* strains.

**Mouse infections.** Female BALB/c mice (Taconic, Germantown, N.Y.) (7 to 8 weeks old) were used for all animal experiments. Mice were subjected to fasting for 16 h prior to infection; meanwhile, bacteria were grown in Luria-Bertani broth for 16 h to stationary phase. Values of optical density at 600 nm were used to determine cell density, and cultures were adjusted to an appropriate concentration in sterile phosphate-buffered saline. Mice were inoculated with 0.2 ml of bacteria orogastrically through a 20-gauge feeding needle, after which mice were provided with food and water ad libitum. Bacteria were plated on L plates containing irgasan (2  $\mu$ g/ml) to determine the actual dose administered. For competition experiments, plated bacteria (input) were counted and then patched or replica plated onto kanamycin plates (50  $\mu$ g/ml) to determine the ratio of mutant (Kan<sup>s</sup>) to wild-type (Kan<sup>r</sup>) bacteria in the inoculum. At 1, 2, or 5 days postinfection, mice were sacrificed by CO<sub>2</sub> asphyxiation and tissues were harvested and placed into preweighed tubes with 1 ml of sterile phosphate-buffered saline-15% glycerol. For most experiments, harvested tissues included the spleen, the MLN, the cecal lymph follicle (CLF) located at the apex of the cecum, PP, and the intestinal contents of the ileum (terminal third of the small intestine), the cecum, and the ascending colon (first third of the large intestine). To collect intestinal contents, intestines were cut into pieces approximately 1




FIG. 1. Colonization of intestinal and lymph tissues at day 1 and day 2 postinfection with  $2 \times 10^9$  CFU of wild-type *Y. pseudotuberculosis* (filled diamonds), *yopHEMOJ* (open circles), or *yopBHEMOJ* (open triangles). Data from four to six mice from two experiments were pooled. Each symbol represents the  $\log_{10}$  CFU/gram of tissue from one mouse colonized with the appropriate strain. All points were above the limit of detection of 10 CFU/gram of tissue. At day 1, colonization by *yopHEMOJ* and *yopBHEMOJ* was statistically different (\*\*;  $P < 0.01$ ) from that by the wild-type strain in the ileum, colon, and PP. At day 2, colonization by *yopHEMOJ* and *yopBHEMOJ* are statistically different from the wild-type strain ( $P < 0.01$ ) in all tissues.

inch long and, using forceps, contents were squeezed into the collection tube. Tissues were weighed and then mechanically homogenized using a Tissue Tearor apparatus (Biospec Products Inc., Bartlesville, Okla.). Dilutions of tissue homogenate were plated on L plates containing 2  $\mu$ g of irgasan/ml to determine CFU/gram of tissue. For most experiments, two to four mice were infected with each *Y. pseudotuberculosis* strain being tested and experiments were repeated two to four times.

For single-strain infections, all data were transformed logarithmically and expressed in graphs as  $\log_{10}$  CFU/gram of tissue. Averages, ratios, and  $P$  values were determined from the logarithmically transformed values. When less than 1 bacterium was recovered at a dilution of  $10^{-1}$ , a value of 1 CFU was used to determine the minimal CFU/gram of tissue.  $P$  values were determined by a two-tailed, unpaired Student's  $t$  test by comparing colonization by the wild-type bacteria to colonization by the *yop* mutants. Data with  $P$  values of  $< 0.01$  were considered to be statistically significant.

For competition experiments, after determination of the total CFU/gram of tissue (mutant and wild-type bacteria), colonies were patched or replica plated onto kanamycin plates to determine the ratio of mutant (Kan<sup>s</sup>) to wild-type (Kan<sup>r</sup>) bacteria in each tissue (output). Data for the competition experiments are expressed as a competitive index (C.I.) as follows: C.I. = (mutant/wild-type output ratio)/(mutant/wild-type input ratio). For competition experiments, tissues containing less than 50 total bacteria in the  $10^{-1}$  dilution were not included in the results. When less than 1 mutant bacterium was recovered from the tissue homogenate, a value of 1 was used to determine the minimum C.I. for the tissue. In most cases, the limit of detection was 1 mutant bacterium:200 wild-type bacteria. Competition data were transformed logarithmically to determine the geometric means of the C.I. and  $P$  value.  $P$  values were determined in a two-tailed, unpaired Student's  $t$  test comparing the C.I. for mice infected with the two wild-type strains with that for mice infected with a *yop* mutant and the wild-type Kan<sup>r</sup> strain. A  $P$  value of  $< 0.01$  was used as the critical value for significance.

Competitions between *yopHE* and *yopHEMOJ* and between *yopHEO* and *yopHEMOJ* were conducted with Kan<sup>r</sup> *yopHE* and *yopHEO* strains and Kan<sup>s</sup> *yopHEMOJ*. C.I. values were determined as follows: [*yopHE(O)*/*yopHEMOJ* output ratio]/[*yopHE(O)*/*yopHEMOJ* input ratio].

The Institutional Animal Care and Use Committee of Tufts University approved all animal procedures.

**Weight and morphology studies.** Mice were weighed daily during single-strain experiments. Percent weight loss or gain was determined by dividing the final weight at day 5 by the initial weight at day 1. Morphology observations were initially made during nonblind experiments; however, results were confirmed in two blind experiments. Tissue morphology was ranked as follows: 0, healthy

tissues; 1, moderate signs of disease; and 2, severe signs of disease. The following characteristics were used to assign a morphology rank: for the ileum and cecum, when the intestines were full of green contents they were ranked 0 (healthy tissue); when the contents were not full and a mixture of green and clear was seen, they were ranked 1 (moderate disease); and when the intestines were not full and any contents were clear, they were ranked 2 (severe disease). For the ascending colon, healthy tissue (0) was indicated by the presence of pellets throughout the colon, moderate disease (1) was indicated by presence of pellets in the transverse and descending colon but the absence of pellets in the ascending colon, and severe disease (2) was indicated by the absence of pellets throughout the colon.

**Histology.** Mice were infected with  $5 \times 10^8$  CFU of wild-type *Y. pseudotuberculosis*, *yopB*, *yopE*, *yopH*, or *yopO*. At 2 and 5 days postinfection, mice were sacrificed and tissues were harvested for histology. The terminal PP located closest to the cecum and a MLN were isolated. Tissues were fixed in 4% formalin for 2 h, washed in ethanol, and embedded in paraffin. Sections (10  $\mu$ m thick) were cut and stained with hematoxylin and eosin.

## RESULTS

**Effector Yops are required for colonization in intestinal and lymph tissues.** Previously, a signature-tagged mutagenesis study identified five mutants in the plasmid-encoded type III secretion-translocation system as unable to compete with wild-type *Y. pseudotuberculosis* for colonization of the cecum (40). This result suggested that either the type III secretion-translocation apparatus itself or one or more of the effector Yops play an essential role in colonization and/or persistence in the intestines. To determine whether known effector Yops are required for colonization of the intestines, a *yopHEMOJ* mutant strain, lacking five Yops, was tested in BALB/c mice (Fig. 1). To determine whether other as-yet-unidentified effector Yops or the translocation apparatus itself is required for colonization, the behavior of a *yopBHEMOJ* strain, which is lacking five effector *yops* and is defective for protein translocation, was compared to that of both the *yopHEMOJ* strain and wild-



type *Y. pseudotuberculosis* (Fig. 1). Mice were sacrificed at 1 or 2 days postinfection, and the numbers of CFU/gram of tissue in the lumen of the ileum, cecum, and ascending colon and the PP, MLN, and CLF were determined. At day 1, both the *yopHEMOJ* and *yopBHEMOJ* mutants showed 10- to 100-fold defects ( $P < 0.01$ ) in colonization of the ileum, ascending colon, and PP compared to wild-type *Y. pseudotuberculosis*, suggesting that at least one of the five effector Yops absent from the *yopHEMOJ* strain is important for initial colonization of the ileum, ascending colon, and PP.

Between 1 and 2 days postinfection, the average number of wild-type *Y. pseudotuberculosis* bacteria increased 10- to 100-fold in all tissues, while *yopHEMOJ* and *yopBHEMOJ* mutants decreased 3- to 40-fold in all tissues except the CLF and MLN, where the numbers remained constant. The colonization of the *yopHEMOJ* and *yopBHEMOJ* strains at day 2 ranged from 25-fold to  $2 \times 10^4$ -fold lower than that of the wild-type strain ( $P < 0.01$ ). These results indicate that at least one of the five effector Yops is crucial for persistence and replication in the intestines and PP and for replication in the CLF and MLN. No differences were detected between the *yopHEMOJ* and *yopBHEMOJ* mutants ( $P > 0.1$ ), suggesting that neither the translocation of other effectors nor the translocation apparatus itself has any additional major role in colonization of the GI tract and lymph tissues in the absence of YopH, YopE, YopM, YopO, and YopJ.

#### Analysis of *yop* mutants in single-strain oral inoculations.

To determine whether any one Yop is required for colonization and persistence in intestinal and lymph tissues, infections with *yop* deletion strains were compared to infections with wild-type *Y. pseudotuberculosis* in single-strain infections. Mice were orogastrically inoculated with  $2 \times 10^9$  CFU (high dose) or  $2 \times 10^8$  CFU (low dose) of wild-type, *yopB*, *yopH*, *yopE*, or *yopO* bacteria. These *yop* mutants were chosen because previously published data (44) and our unpublished results indicate that YopJ and YopM do not play a role in colonization of the intestines. At 2 or 5 days postinfection, mice were sacrificed and the numbers of CFU/gram of ileum, cecal, and ascending colon exudates and PP, MLN, and CLF were determined (Fig. 2 and Table 2). At day 2 postinfection in both high- and low-dose experiments, wild-type *Y. pseudotuberculosis* was recovered from intestinal exudates, PP, and CLF at (on average)  $10^5$  to  $10^7$  CFU/g of tissue (Fig. 2 and Table 2). In the low-dose infections, the levels of colonization were 5- to 10-fold lower and more variation of CFU/gram of tissue was observed. In the high-dose experiments, the number of bacteria recovered from all tissues decreased from day 2 to day 5, while in the low-dose experiment, the levels of wild-type *Y. pseudotuberculosis* remained relatively constant in the intestines but decreased in the PP and MLN. The decrease in CFU in the high-dose infections from day 2 to day 5 suggested that those mice infected with the higher dose might have had a stronger immune response or more pronounced gastroenteritis between day 2 and 5 and, thus, that the ability of *Y. pseudotuberculosis* to persist and/or replicate was hampered by host defenses.

The translocation mutant, *yopB*, colonized the intestinal tissues, PP, and CLF at a level 200- to 7,000-fold lower than the wild-type *Y. pseudotuberculosis* at day 2 ( $P < 0.01$ ), regardless of the inoculation dose (Fig. 2 and Table 2). In fact, the *yopB* mutant was not recovered from some tissues (Fig. 2), indicat-

ing that less than 10 bacteria were present (Table 2). The levels of the *yopB* mutant remained consistent or increased between day 2 and day 5. Most notably, in the lymph tissues at day 5 of the low-dose infections, the *yopB* mutant was recovered at levels 7- to 42-fold higher than at day 2, indicating that the *yopB* mutant could replicate in these tissues. The combination of an increase in the number of *yopB* mutant bacteria and a decrease in the number of wild-type bacteria in the lymph tissues meant that at day 5, some of the differences between colonization of the *yopB* mutant and wild-type strains in the MLN, PP, and CLF were not statistically significant (Fig. 2E, F, K, and L and Table 2). The difference in the course of infection between the wild-type strain and the *yopB* mutant could have been due to a slower rate of replication of the *yopB* mutant during infection, although no defect in replication was observed at 37°C in L broth or tissue culture medium with any *yop* mutant strain (data not shown). Alternatively, the *yopB* mutant may have colonized or seeded tissues less efficiently than the wild-type strain but, once established, was capable of replication in some tissues.

None of the effector *yop* mutant strains *yopH*, *yopE*, or *yopO* was as defective as the *yopB* mutant in colonizing intestinal or lymph tissues, with one exception (Fig. 2 and Table 2). The *yopH* mutant colonized at levels comparable to or even lower than those of the *yopB* mutant in the MLN in all experiments and in the CLF at day 5 (Fig. 2 and Table 2). In all other tissues, the *yopH* mutant had 2- to 15-fold defects at day 2, which were at most moderately significant ( $P = 0.01$  to 0.1). These defects were usually not apparent at day 5, because in the low-dose experiment the levels of colonization by the *yopH* mutant increased 2- to 30-fold from day 2 to day 5 and in the high-dose experiment the levels of *yopH* mutant decreased less than those of the wild-type strain. Thus, colonization by a *yopH* mutant was comparable to that by wild-type *Y. pseudotuberculosis* in most tissues at 5 days postinfection (Table 2). These results indicate that a *yopH* mutant can persist and replicate in the GI tract and PP but not in the MLN and CLF. As with the *yopB* mutant, the increase in the levels of bacterial recovery between day 2 and day 5 suggests a defect in initial colonization or seeding of tissues.

In both low- and high-dose infections, the *yopE* mutant was recovered at levels 3- to 20-fold lower than wild-type *Y. pseudotuberculosis* in all tissues at day 2 and many of these defects were at least moderately significant ( $P = 0.01$  to 0.1). By day 5, moderately significant, 4- to 5-fold differences between wild-type *Y. pseudotuberculosis* and *yopE* were observed only in the ileum and PP at both infectious doses. In the ileum and PP, the levels of the *yopE* mutant decreased from day 2 to day 5, while in most other tissues the levels of the *yopE* mutant increased. Thus, the *yopE* mutant appeared to initially colonize all tissues less well than the wild-type strain but was capable of persisting and replicating in all tissues except the ileum and PP.

Of the *yop* effector mutants, the *yopO* strain appeared most similar to wild-type *Y. pseudotuberculosis*. The *yopO* mutant, like the wild-type strain, failed to persist in all tissues except the MLN at the high dose, presumably due to heightened host defenses to infection (Fig. 2 and Table 2).

At 5 days postinfection, most mice infected with wild-type *Y. pseudotuberculosis* were colonized with about  $10^4$  CFU/g in the spleen (Fig. 3). In contrast, the *yopH* and *yopE* mutants were



TABLE 2. Average log<sub>10</sub> CFU/gram of tissue at day 2 and day 5 postinfection

Dose level and tissue	Avg log <sub>10</sub> CFU/g of tissue and log <sub>10</sub> ratio on:																	
	Day 2 postinfection									Day 5 postinfection								
	wt avg <sup>a,d</sup>	<i>ΔyopB</i>		<i>ΔyopH</i>		<i>ΔyopE</i>		<i>ΔyopO</i>		wt avg <sup>e</sup>	<i>ΔyopB</i>		<i>ΔyopH</i>		<i>ΔyopE</i>		<i>ΔyopO</i>	
	Avg <sup>d</sup>	Ratio <sup>b,c</sup>	Avg <sup>d</sup>	Ratio	Avg <sup>d</sup>	Ratio	Avg <sup>d</sup>	Ratio		Avg <sup>d</sup>	Ratio <sup>b,c</sup>	Avg <sup>e</sup>	Ratio	Avg <sup>e</sup>	Ratio	Avg <sup>e</sup>	Ratio	
<b>High</b>																		
Tissues																		
Ileum	5.8	2.6	<b>0.0006</b>	5.5	0.44	4.8	<u>0.09</u>	5.5	0.48	4.9	2.8	<b>0.01</b>	4.7	0.79	4.3	<u>0.26</u>	4.6	0.62
Cecum	6.2	3.9	<u>0.005</u>	5.5	0.2	5.0	<u>0.06</u>	5.9	0.52	5.1	3.4	<b>0.02</b>	5.1	0.96	5.3	<u>1.49</u>	4.8	0.56
Colon	6.2	3.2	<b>0.001</b>	5.0	<b>0.07</b>	5.2	<b>0.09</b>	6.2	0.95	5.4	3.1	<b>0.005</b>	5.4	0.96	5.8	2.35	5.5	1.28
PP	7.0	3.8	0.0007	6.0	<u>0.11</u>	5.8	<b>0.06</b>	6.3	0.2	5.2	4.2	0.1	5.1	0.8	4.4	<u>0.17</u>	4.6	0.27
CLF	6.8	4.1	<b>0.002</b>	5.1	<b>0.02</b>	6.2	<u>0.23</u>	6.1	<u>0.17</u>	5.0	4.1	0.14	3.3	<b>0.02</b>	4.4	<u>0.23</u>	4.3	0.21
MLN	4.9	3.6	<u>0.05</u>	3.5	<u>0.04</u>	4.3	<u>0.25</u>	4.7	0.6	4.7	4.2	0.39	3.1	<b>0.03</b>	4.5	0.77	4.7	0.98
Spleen	2.9	2.1	0.17	2.8	0.95	2.1	0.17	2.6	0.52	4.2	2.3	<u>0.01</u>	2.6	<b>0.02</b>	2.3	<b>0.012</b>	3.4	0.15
<b>Low</b>																		
Tissues																		
Ileum	5.0	2.5	<b>0.003</b>	3.9	0.07	4.5	0.29	5.5	2.85	5.1	3.0	<b>0.008</b>	5.4	1.9	4.2	<u>0.14</u>	4.2	<u>0.12</u>
Cecum	5.8	2.6	<b>0.0007</b>	4.7	<u>0.08</u>	4.8	0.1	5.8	1	5.6	2.8	<b>0.002</b>	5.1	<u>0.37</u>	5.6	1.15	5.2	0.38
Colon	5.5	2.9	<b>0.002</b>	4.5	<u>0.1</u>	5.1	0.34	5.8	1.91	5.7	3.4	<b>0.005</b>	5.5	0.62	5.9	1.47	5.5	0.65
PP	6.6	2.7	<b>0.0001</b>	4.5	<u>0.008</u>	5.8	0.18	5.7	0.14	5.8	4.1	<b>0.02</b>	5.5	0.53	5.1	<u>0.2</u>	4.6	<u>0.07</u>
CLF	5.9	3.5	<b>0.004</b>	4.8	0.08	5.2	0.2	6.5	4.16	5.6	4.3	<u>0.05</u>	4.2	<b>0.04</b>	5.5	0.86	4.9	0.22
MLN	3.9	2.9	<u>0.12</u>	2.6	<b>0.05</b>	2.9	<u>0.12</u>	4.2	2.47	4.5	4.0	0.25	2.7	<b>0.01</b>	3.8	0.16	4.2	0.48
Spleen	3.2	2.1	<u>0.08</u>	2.1	<u>0.08</u>	2.3	<u>0.11</u>	2.9	0.45	4.2	2.7	<u>0.03</u>	2.2	<b>0.01</b>	2.0	<b>0.007</b>	3.0	<u>0.06</u>

<sup>a</sup> avg, average of log<sub>10</sub> CFU/gram of tissues. wt, wild type.

<sup>b</sup> Ratio of average log<sub>10</sub> (CFU of mutant/gram of tissue)/(average log CFU of wild type/gram of tissue).

<sup>c</sup> Significant differences from wild type are indicated as follows: boldface,  $P < 0.01$ ; underlined values,  $P$  value is between 0.01 and 0.1.

<sup>d</sup>  $n =$  four mice pooled from two experiments.

<sup>e</sup>  $n =$  six to eight mice pooled from three to four experiments.

not recovered from the spleens of many infected mice; when bacteria were recovered, the amount was lower than that of the wild-type strain. The reduced ability of the *yopH* and *yopE* mutants to colonize the spleen is consistent with previous studies using oral and intravenous inoculations (5, 9, 30, 65). The *yopO* mutant was able to colonize the spleen at day 5 at levels similar to or slightly lower than that of the wild-type strain. These data are in contrast to those of Galyov et al. (23) in which a *yopO* mutant failed to colonize the spleens of mice following oral inoculation. However, the strain used by Galyov also contains a mutation in *yadA* which may have had an additional detrimental effect on colonization of the spleen. Colonization of the liver was not examined in these experiments; in other experiments, however, colonization of the spleen correlated with colonization of the liver (unpublished data).

In summary, the effector *yop* mutants, *yopH*, *yopE*, and *yopO*, had modest defects in colonization, persistence, and/or replication in the GI tract and most lymph tissues. With the exception of the *yopH* mutant in the MLN and CLF, no one *Yop* effector was responsible for the lack of colonization and persistence of the *yopB* and *yopHEMOJ* mutants. These results suggest either that two or more *Yops* have redundant functions in colonization or that multiple-*Yop*-dependent mechanisms are used by *Y. pseudotuberculosis* to ensure colonization.

**Host signs of disease in response to single *yop* mutants.** Although the *yopH* and *yopE* mutants had at most sevenfold defects in colonization of intestinal exudates and PP at day 5, the appearance of the intestinal tissues during dissection was noticeably different from that of tissues colonized with wild-type *Y. pseudotuberculosis*. Intestinal exudates of mice infected

with wild-type *Y. pseudotuberculosis* or the *yopO* mutant showed obvious changes in color and consistency compared to exudates of uninfected mice.

Additionally, these mice lost on average 11 to 15% of their initial body weight during the course of the 5-day infection. In contrast, mice infected with the *yopH* or *yopE* mutants showed changes in the ileal exudates only and did not lose weight during the infection (data not shown). These changes were distinct from the changes observed in mice that were subjected to fasting, suggesting that anorexia caused by illness was not solely responsible but rather that the colonizing bacteria were also inducing changes in intestinal tissues. Thus, weight loss correlated with changes in the cecal and colonic exudates and with colonization of the spleen by *Y. pseudotuberculosis*.

In mice infected with wild-type *Y. pseudotuberculosis* or with the *yopH*, *yopE*, and *yopO* mutants, histological examination of the PP and the MLN revealed inflammation (data not shown). The structural integrity of the germinal center of the lymph node in the PP was compromised, as the distinct border between the germinal center and the regions of B and T cells was destroyed. In some mice, furthermore, the influx of macrophages and granulocytes (predominantly eosinophils) in the PP and the lamina propria of neighboring intestinal villi was apparent at day 5, although the villi remained intact. In the MLN, abscesses and apoptotic cells were visible in mice infected with the wild-type strain or the *yopH*, *yopE*, or *yopO* mutants. Thus, in these preliminary experiments, no obvious differences were seen in the pathology of the MLN, the PP, or the surrounding ileal tissues of mice infected with wild-type, *yopH*, *yopE*, or *yopO* bacteria. The histological results support the visible changes seen in the ileum of all infected mice and indicate that






FIG. 4. Colonization of intestinal and lymph tissues at day 2 and day 5 postinfection with  $2 \times 10^8$  CFU of wild-type, *yopHE* ( $\Delta$ HE), *yopHO* ( $\Delta$ HO), *yopEO* ( $\Delta$ EO), *yopHEO* ( $\Delta$ HEO), or *yopHEMOJ* ( $\Delta$ HEMOJ) *Y. pseudotuberculosis*. Data from four to six mice from two to three experiments were pooled. Each symbol represents the  $\log_{10}$  CFU/gram of tissue for the tissue sample from one mouse. Shaded bars represent the average  $\log_{10}$  CFU/gram of tissue. Open symbols indicate that less than 10 CFU were recovered/tissue. Asterisks indicate statistical significance of difference between colonization levels of *yop* mutants and wild-type bacteria. \*,  $P = 0.1$  to 0.01; \*\*,  $P < 0.01$ .






FIG. 5. Competition of *yopHE* versus *yopHEMOJ* (closed circles) and *yopHEO* versus *yopHEMOJ* (open circles), 1 day postinfection with  $2 \times 10^9$  CFU of an equal mixture of *yopHE* and *yopHEMOJ* or *yopHEO* and *yopHEMOJ*. Data from three to six mice from two experiments were pooled. Data are graphed as C.I.  $\{[yopHE(O)/yopHEMOJ \text{ output ratio}]/[yopHE(O)/yopHEMOJ \text{ input ratio}]\}$  values for the tissue samples from one mouse. Shaded bars represent geometric means of the C.I. values. All points were above the limit of detection.

terminated (Fig. 5). The *yopHE* and *yopHEO* mutants out-competed the *yopHEMOJ* strain in all tissues, indicating that other Yops play minor roles in initial colonization. It was notable, however, that the *yopHE* mutant outcompeted the *yopHEMOJ* mutant by more than 10-fold in the ileum and PP and that the *yopHEO* mutant outcompeted the *yopHEMOJ* mutant by less than 10-fold, suggesting that YopO aids in the colonization of the ileum and PP.

***yop* mutant phenotypes are more severe in competition infections.** Competition infections were performed to determine whether the presence of wild-type *Y. pseudotuberculosis* affects the ability of the effector *yop* mutants to colonize tissues. Wild-type bacteria could adversely affect *yop* mutants by competing for colonization sites or by inducing host defenses that the *yop* mutants cannot overcome. Alternatively, the presence of wild-type *Y. pseudotuberculosis* could aid the *yop* mutants, since Yop proteins act outside of the bacteria to alter host cell behavior. Mice were orogastrically infected with  $2 \times 10^9$  bacteria in an inoculum comprised of an equal mixture of the Kan<sup>r</sup> wild-type strain and Kan<sup>s</sup> *yop* mutant strains. A high infectious dose was used to ensure consistent, high levels of wild-type bacteria early in infection (compare low- and high-dose levels of colonization as shown in Fig. 2A to C and 2D to F). Mice were sacrificed at 5 days postinfection, tissues were harvested, and the C.I. was determined (Fig. 6). As a control and for comparison in statistical analysis (see Materials and Methods), the Kan<sup>r</sup> wild-type strain was competed against the isogenic Kan<sup>s</sup> wild-type strain. As expected, the experimental C.I. values for these strains hovered around 1 for all tissues (Fig. 6). When the *yopHEMOJ* or *yopB* mutants were competed against wild-type *Y. pseudotuberculosis*, the mutants were not recovered from the majority of tissues samples, as shown in Fig. 6 (limit of detection, approximately 1:200), and were out-competed by the wild-type strain by at least 16- to 160-fold ( $P < 0.01$ ).

The three effector *yop* mutants each had a distinct pattern of survival, but all showed greater deficiencies in colonization in

the presence of wild-type *Y. pseudotuberculosis* than were observed in the single-strain infections. The *yopH* mutant had the most drastic phenotype; it was below the limit of detection (1:200) in many tissue samples and was outcompeted by the wild-type strain at least 15- to 55-fold ( $P < 0.01$ ) in all tissues (Fig. 6 and Table 3). The inability to recover the *yopH* mutant at day 5 in competition studies was in stark contrast to the relatively high levels of the *yopH* mutant seen in the high-dose single-strain infections at day 5. The ratios of the *yopH* mutant to wild-type *Y. pseudotuberculosis* in the PP and all intestinal tissues were equal to or greater than 0.79 in the high-dose single-strain infection (Table 2), whereas the average C.I. values in these tissues were less than 0.05 (Table 3). The *yopE* mutant also survived less well in the presence of the wild-type strain, with 3- to 30-fold defects ( $P < 0.01$ ) in all tissues. The most severe *yopE* defects were observed in the ileum and PP, the same tissues as showed the day 5 defects in the single-strain infections. The average C.I. values for the *yopE* mutant in the ileum and PP were 0.017 and 0.024, respectively (Table 3), while the ratios of recovered *yopE* mutant versus the wild-type strain in the high-dose single-strain infections were 0.26 and 0.17 in the ileum and PP, respectively (Table 2). In the cecum and colon, the *yopE* mutant was significantly outcompeted by wild-type bacteria. This is in contrast to the results of the single-strain infections, in which the *yopE* mutant was recovered at levels comparable to those of the wild-type strain (Table 2). The *yopO* mutant was outcompeted by the wild-type strain at least 39-fold in the PP and 6- to 8-fold in the MLN, CLF, and ileum ( $P < 0.01$ ), while no defects were seen in the cecum and colon (Table 3).

To determine whether the failure of the *yop* mutants to compete with wild-type *Y. pseudotuberculosis* was due to events occurring early in infection, the *yop* mutants were tested for their ability to compete with wild-type *Y. pseudotuberculosis* in the cecum, PP, and MLN at day 2. In general, the C.I. values for the cecum, PP, and MLN at day 2 were remarkably similar to the ratios of *yop* mutant to wild-type bacteria recovered in these tissues in the high-dose single-strain infections (Table 3 and Table 2). For instance, in the PP the ratio of the *yopH* mutant to the wild-type strain in single-strain infections (Table 2) and the C.I. (Table 3) were 0.11 and 0.15, respectively, and in the cecum, the ratio was 0.2 and the C.I. was 0.19. The C.I. values for the *yopE* mutant in the cecum and PP (0.26 and 0.16) were actually higher than the ratios between *yopE* and the wild-type strain in single-strain infections (0.09 and 0.06), indicating that at day 2 the presence of wild-type *Y. pseudotuberculosis* may be slightly advantageous to the *yopE* mutant in colonizing the cecum and PP. Therefore, we conclude that although the *yop* mutants colonize at lower levels than the wild-type strain at day 2, the presence of wild-type *Y. pseudotuberculosis* did not further impede the ability of the *yop* mutants to initially seed and colonize the cecum, MLN, and PP. Between day 2 and day 5, however, wild-type *Y. pseudotuberculosis* severely inhibited the ability of the *yop* mutants to persist.

## DISCUSSION

Oral inoculation of mice with a lethal dose of *Y. pseudotuberculosis* is a multifaceted process that involves bacterial col-




FIG. 6. Competition between wild-type *Y. pseudotuberculosis* and *yop* mutants at 5 days postinfection with  $2 \times 10^9$  CFU of a mixture of equal amounts of the wild-type strain and either *yopB*, *yopH*, *yopE*, *yopO*, or *yopHEMOJ*. Data from six to eight mice from three to four experiments were pooled. Each point represents the C.I. [(mutant/wild-type output ratio)/(mutant/wild-type input ratio)] value for the tissue sample from one mouse. Shaded bars represent the geometric means of the C.I. values. Open symbols indicate that the *yop* mutant was below the limit of detection, which was usually 200 bacteria. Asterisks indicate the *yop* mutants that were significantly outcompeted by wild-type bacteria (\*,  $P = 0.1$  to  $0.01$ ; \*\*,  $P < 0.01$ ).

onization and replication in a variety of tissues followed by spread to organs concomitant with a rise in the host inflammatory response and disease symptoms. At 24 h after ingestion of wild-type *Y. pseudotuberculosis*, the bulk of the inoculating dose has passed through the GI tract or has been killed; however, some bacteria survive and colonize the ileum, cecum, ascending colon, PP and MLN. By 48 h after infection, bacterial numbers increase in these tissues and seeding of the spleen and liver is observed. In addition, there is a clear host response to infection as the numbers of granulocytes and macrophages increase in the PP and MLN. Between day 2 and day 5, the numbers of *Y. pseudotuberculosis* continue to increase in the spleen and liver but the numbers of bacteria recovered from

many of the initial sites of colonization decrease and weight loss and other signs of disease are observed. Given these parameters of wild-type *Y. pseudotuberculosis* infection, we have examined a set of isogenic *yop* mutant strains for their ability to colonize, persist, and replicate in the GI tract, lymph tissues, and the spleen in single-strain infections and in the context of infection with wild-type *Y. pseudotuberculosis*. As reported here, a strain lacking the five effector Yops failed to colonize any of these tissues in either single-strain or competition studies. Deletion of either *yopH* or *yopE* generally caused lower levels of colonization at day 2 but allowed normal levels in intestinal and lymph tissues in single-strain infections by day 5. Nonetheless, the absence of YopH prevented colonization of

TABLE 3. Geometric mean of C.I. at day 2 and day 5<sup>a</sup>

Tissue	C.I. geometric mean										
	wt/wt Kan		$\Delta yopB$ /wt Kan		$\Delta yopH$ /wt Kan		$\Delta yopE$ /wt Kan		$\Delta yopO$ /wt Kan		$\Delta yopHEMOJ$ /wt Kan day 5
	Day 2	Day 5	Day 2	Day 5	Day 2	Day 5	Day 2	Day 5	Day 2	Day 5	
Ileum		0.7		<b>0.021</b>		<b>0.047</b>		<b>0.024</b>		<u>0.094</u>	<b>0.015</b>
Cecum	0.85	0.63	<b>0.008</b>	<b>0.009</b>	<b>0.19</b>	<b>0.026</b>	<b>0.26</b>	<b>0.078</b>	0.58	<u>0.2</u>	<b>0.006</b>
Colon		0.45		<b>0.01</b>		<b>0.014</b>		<b>0.073</b>		0.24	<b>0.005</b>
PP	0.70	1.12	<b>0.006</b>	<b>0.022</b>	<b>0.15</b>	<b>0.02</b>	<b>0.16</b>	<b>0.04</b>	0.65	<b>0.03</b>	<b>0.012</b>
CL		0.89		<b>0.013</b>		<b>0.017</b>		<u>0.085</u>		<u>0.11</u>	<b>0.005</b>
MLN	0.81	0.54	<b>0.051</b>	<b>0.032</b>	<b>0.07</b>	<b>0.02</b>	<u>0.19</u>	<u>0.2</u>	0.82	<b>0.097</b>	<b>0.012</b>

<sup>a</sup> Geometric mean of the C.I. from six to eight mice pooled from three to four experiments. C.I. for mutant/wild type that were statistically significant from the C.I. for wild type/wild type are indicated as follows: boldface,  $P < 0.01$ ; underlined characters,  $P$  value is between 0.01 and 0.1. wt, wild type.

the MLN. In contrast to the *yopH* and *yopE* mutants, a *yopHE* strain was as defective as the *yopHEMOJ* strain at both day 2 and day 5, indicating that YopH and YopE play crucial roles in the first 24 h of infection.

Since the biochemical activities of YopH, a tyrosine phosphatase (9, 27), and YopE, a Rac-GAP (5, 69), are different, these two Yops may ensure bacterial colonization by inactivating the same cell types via different mechanisms. Thus, in the absence of one Yop, the presence of the other would still be sufficient to at least partially block host cell function. While this hypothesis is theoretically attractive, several laboratories have observed that in the absence of either YopH or YopE, *Yersinia* becomes susceptible to phagocytosis by neutrophils and macrophages in cell culture, indicating that the remaining Yops are not sufficient to completely thwart phagocytosis (1, 2, 9, 26). Thus, either this hypothesis is not correct or, in an animal infection model, *Y. pseudotuberculosis yopH* and *yopE* mutants can still block phagocytosis by cells encountered during infection. A second possibility is that YopH and YopE have distinct roles in colonizing tissues and thus that in the absence of one Yop, the other Yop can still promote colonization, although less efficiently than when both Yops are present. In this scenario, one might postulate that the bacteria colonize multiple different niches. Future experiments directed at determining the locations of the wild-type strain, *yopH* and *yopE* mutants, and the host cell targets of YopH and YopE in the GI tract and PP should distinguish between these two possibilities.

While it is likely that loss of the YopE Rac-GAP activity, which renders *Y. pseudotuberculosis* susceptible to phagocytosis by host cells, is the reason why the *yopE* mutant colonizes less efficiently than the wild-type strain, it has also been shown that in the absence of YopE, *Y. pseudotuberculosis* acquires novel phenotypes. Specifically, an increase in host cell death is observed after infection with a *yopE* mutant, apparently because YopE activity blocks leakage from the pore formed by YopB and the translocation apparatus (5, 68). In the mouse, this leakage could result in more tissue damage and inflammation. However, these assays were done in cell culture at a multiplicity of infection of 100 bacteria per host cell, which is likely to be considerably higher than that occurring in a natural infection of the mouse. Nonetheless, it is conceivable that some of the properties of mice infected with strains lacking *yopE* are due to cytotoxicity caused by the translocation apparatus.

It is interesting that the *yopB* mutant is able to persist in the lymph tissues to day 5 postinfection while *yopH* and *yopJ* (44) mutant strains cannot. The results with the *yopB* mutant are consistent with previous reports and unpublished data (J. M. Balada and J. Mecsas, unpublished data) showing that mutants lacking the type III secretion system colonize the MLN (25, 37). The presence of a type III secretion-translocation apparatus may alert the host to the presence of the bacteria via the innate immune response. Alternatively, an imbalance of Yop activities on host cells (due to deletion of some effector *yops*) may enhance bactericidal host defenses.

Regardless of the precise biochemical and phenotypic defect of a particular *yop* mutant, the observation that a given *yop* mutant behaves differently in different tissues suggests that there are distinct mechanisms by which the bacteria colonize and persist in different tissues. For instance, the *yopH* mutant strain was unable to colonize the MLN but was proficient in

colonization of the PP in single-strain infections. In contrast, the *yopE* and *yopO* mutants showed modest defects in colonizing the PP but colonized the MLN as well as did wild-type *Y. pseudotuberculosis*. These results indicate that the environment of the MLN is significantly different than that of the PP, despite both being lymph nodes containing similar cell types. In contrast to differences between colonization of the PP and MLN, phenotypes in the PP generally mirrored phenotypes in the ileum but not in the cecum or ascending colon. This observation might reflect continual reseeding of the PP from the ileum (or vice versa) but also demonstrates that the environment of the ileum is distinct from those of the cecum and ascending colon with regard to the ability of the *yop* mutants to colonize.

The fact that YopH and YopE are necessary for colonization and replication of the GI tract is somewhat surprising in light of the observations that YopH and YopE prevent internalization of *Yersinia* by epithelial cells in cell culture (1, 2, 5, 8, 18, 26, 41, 55–57). If YopE and YopH prevent phagocytosis or internalization of bacteria during infection, how is *Y. pseudotuberculosis* internalized by M cells (3, 13, 29, 38, 42)? There are several possible explanations. First, YopH and YopE may not be expressed when *Y. pseudotuberculosis* attaches to and transverse through M cells. This explanation implies that *Y. pseudotuberculosis* invades M cells prior to Yop expression and that once Yops are expressed, no additional PP colonization occurs via M cells. A second possibility is that YopH and YopE are not delivered into M cells. However, a study of *Yersinia* infection in a cell culture system that involved generation of M-like cells demonstrated that Yops reduce transcytosis of bacteria through the M-like cells, suggesting that Yops are translocated into these M-like cells (62). There are however, differences between the M-like cells derived in cell culture and M cells found in the small intestine of mice. Most notably, the M-like cells bound by *Yersinia* are largely UEA1<sup>-</sup>, while M cells in the ileum are UEA1<sup>+</sup> (13, 38). Additionally, differences in lectins expressed on cells may alter the ability of *Yersinia* to translocate Yops. In fact, it has been shown that translocation of YopE is sensitive to the types of proteoglycans present on the surface of mammalian cells (12). Therefore, it remains an open question as to whether *Yersinia* Yops are translocated into M cells in the ileum of a mouse. A third possible explanation is that M cells may be able to resist the actions of YopH and YopE. This possibility implies biochemical differences between M cells and other epithelial cells that have not been identified to date.

While this is the first report that specific effector Yops are necessary for initial colonization, persistence, and replication in the GI tract, type III secretion systems and their effector proteins of other enteric pathogens (including EspG of enteropathogenic *E. coli* [17] and proteins regulated by *hilA* in *Salmonella*) have been identified as important in colonization or in provoking diarrheal symptoms in the GI tract. In *Salmonella enterica* serovar Typhimurium, mutations in *hilA* (which encodes a transcriptional activator of the SPI-1 type III secretion system) result in decreased colonization of the small intestine in both single and competition experiments after oral inoculation of mice (47). In a calf oral inoculation model, an *hilA* mutant was not as virulent as wild-type *S. enterica* serovar Typhimurium, as measured by death of the animals and sever-



ity of diarrhea (66). Additionally, the type III effector proteins SopA, SopB, SopD, SopE2, and SipA of *S. enterica* serovar Typhimurium and *S. dublin* are important in causing fluid accumulation in calves (33, 72). It is interesting that *Salmonella* contains an *hilA*-regulated two-domain effector protein, SptP, that has both tyrosine phosphatase and Rac-GAP activities similar to those of YopH and YopE (20, 21). However, an *sptP* mutant colonizes the ileum, PP, and MLN and causes diarrhea in calves at levels comparable to wild-type *S. enterica* serovar Typhimurium (67). Thus, although SptP has biochemical activities similar to those of YopH and YopE, SptP is not playing a similar role in *S. enterica* serovar Typhimurium infection of calves.

The differences in the levels of colonization by the *yopH* and *yopE* mutants in the single-strain and the competition experiments indicate that the presence of wild-type *Y. pseudotuberculosis* affects the ability of the mutants to persist to day 5. There are two likely explanations for the negative impact of the wild-type bacteria on the *yop* mutants. First, the wild-type bacteria may outcompete the *yop* mutants for sites of colonization. We noted that the presence of wild-type bacteria did not affect the ability of the *yop* mutants to colonize at day 2, indicating that the *yopH* and *yopE* mutants were able to find sites of colonization in the presence of wild-type bacteria. However, over the course of 5 days, wild-type *Y. pseudotuberculosis* may continually seed new niches more efficiently than *yop* mutants and thus overtake the mutants. Second, the wild-type bacteria may elicit a strong immune response that the *yop* mutants cannot survive. The second possibility is consistent with the weight and morphology results of the single-strain infections in which *yopE* and *yopH* did not appear to cause disease. In the presence of wild-type bacteria, the *yop* mutants were presumably encountering host defenses that were lacking in the single-strain infections. Additionally, these two possibilities are not mutually exclusive—the *yop* mutants may fail to survive in the presence of the wild-type strain because of a combined inability to efficiently colonize niches and to survive the host immune response. Future work involves distinguishing between these two possibilities and exploiting the competition assay to investigate seeding patterns of different *yop* mutants and to determine host factors that specifically target *yop* mutants.

#### ACKNOWLEDGMENTS

We thank members of the Mecsas lab for thoughtful discussion, Andrew Camilli, Jennifer Coburn, Ralph Isberg, and Abraham L. Sonenshein for critical reading of the manuscript, and Alvar Gustafson for expert advice on histological samples.

This work was supported in part by a Natalie V. Zucker Award, a Charles H. Hood Foundation grant, National Institute of Health grant R21-AI49348, the Center for Gastroenterology Research on Absorptive and Secretory Processes, Tufts-New England Medical Center (NIDDK, P30 DK34928), and startup funds from Tufts University awarded to J.M. L. K. Logsdon was supported by National Institutes of Health training grant T32-AI 07422.

#### REFERENCES

1. Andersson, K., N. Carballeira, K. E. Magnusson, C. Persson, O. Stendahl, H. Wolf-Watz, and M. Fallman. 1996. YopH of *Yersinia pseudotuberculosis* interrupts early phosphotyrosine signalling associated with phagocytosis. *Mol. Microbiol.* **20**:1057–1069.
2. Andersson, K., K. E. Magnusson, M. Majeed, O. Stendahl, and M. Fallman. 1999. *Yersinia pseudotuberculosis*-induced calcium signaling in neutrophils is blocked by the virulence effector YopH. *Infect. Immun.* **67**:2567–2574.
3. Autenrieth, I. B., and R. Firsching. 1996. Penetration of M cells and de-

- struction of Peyer's patches by *Yersinia enterocolitica*: an ultrastructural and histological study. *J. Med. Microbiol.* **44**:285–294.
4. Barz, C., T. N. Abahji, K. Trulzsch, and J. Heesemann. 2000. The *Yersinia* Ser/Thr protein kinase YpkA/YopO directly interacts with the small GTPases RhoA and Rac-1. *FEBS Lett.* **482**:139–143.
5. Black, D. S., and J. B. Bliska. 2000. The RhoGAP activity of the *Yersinia pseudotuberculosis* cytotoxin YopE is required for antiphagocytic function and virulence. *Mol. Microbiol.* **37**:515–527.
6. Black, R. E., R. J. Jackson, T. Tsai, M. Medvesky, M. Shayegani, J. C. Feeley, K. I. MacLeod, and A. M. Wakelee. 1978. Epidemic *Yersinia enterocolitica* infection due to contaminated chocolate milk. *N. Engl. J. Med.* **298**:76–79.
7. Bliska, J. B., and D. S. Black. 1995. Inhibition of the Fc receptor-mediated oxidative burst in macrophages by the *Yersinia pseudotuberculosis* tyrosine phosphatase. *Infect. Immun.* **63**:681–685.
8. Bliska, J. B., M. C. Copass, and S. Falkow. 1993. The *Yersinia pseudotuberculosis* adhesin YadA mediates intimate bacterial attachment to and entry into HEp-2 cells. *Infect. Immun.* **61**:3914–3921.
9. Bliska, J. B., K. L. Guan, J. E. Dixon, and S. Falkow. 1991. Tyrosine phosphate hydrolysis of host proteins by an essential *Yersinia* virulence determinant. *Proc. Natl. Acad. Sci. USA* **88**:1187–1191.
10. Bolin, I., and H. Wolf-Watz. 1988. The plasmid-encoded Yop2b protein of *Yersinia pseudotuberculosis* is a virulence determinant regulated by calcium and temperature at the level of transcription. *Mol. Microbiol.* **2**:237–245.
11. Bottone, E. J. 1997. *Yersinia enterocolitica*: the charisma continues. *Clin. Microbiol. Rev.* **10**:257–276.
12. Boyd, A. P., M. P. Sory, M. Iriarte, and G. R. Cornelis. 1998. Heparin interferes with translocation of Yop proteins into HeLa cells and binds to LcrG, a regulatory component of the *Yersinia* Yop apparatus. *Mol. Microbiol.* **27**:425–436.
13. Clark, M. A., M. A. Jepson, N. L. Simmons, and B. H. Hirst. 1994. Differential surface characteristics of M cells from mouse intestinal Peyer's and caecal patches. *Histochem. J.* **26**:271–280.
14. Cornelis, G. R., A. Boland, A. P. Boyd, C. Geuijen, M. Iriarte, C. Neyt, M. P. Sory, and I. Stainier. 1998. The virulence plasmid of *Yersinia*, an antihist genome. *Microbiol. Mol. Biol. Rev.* **62**:1315–1352.
15. Donnenberg, M. S., and J. B. Kaper. 1991. Construction of an *eae* deletion mutant of enteropathogenic *Escherichia coli* by using a positive-selection suicide vector. *Infect. Immun.* **59**:4310–4317.
16. Dukuzumuremyi, J. M., R. Rosqvist, B. Hallberg, B. Akerstrom, H. Wolf-Watz, and K. Schesser. 2000. The *Yersinia* protein kinase A is a host factor inducible RhoA/Rac-binding virulence factor. *J. Biol. Chem.* **275**:35281–35290.
17. Elliott, S. J., E. O. Krejany, J. L. Mellies, R. M. Robins-Browne, C. Sasakawa, and J. B. Kaper. 2001. EspG, a novel type III system-secreted protein from enteropathogenic *Escherichia coli* with similarities to VirA of *Shigella flexneri*. *Infect. Immun.* **69**:4027–4033.
18. Fallman, M., K. Andersson, S. Hakansson, K. E. Magnusson, O. Stendahl, and H. Wolf-Watz. 1995. *Yersinia pseudotuberculosis* inhibits Fc receptor-mediated phagocytosis in J774 cells. *Infect. Immun.* **63**:3117–3124.
19. Forsberg, A., and H. Wolf-Watz. 1988. The virulence protein Yop5 of *Yersinia pseudotuberculosis* is regulated at transcriptional level by plasmid-pIB1-encoded *trans*-acting elements controlled by temperature and calcium. *Mol. Microbiol.* **2**:121–133.
20. Fu, Y., and J. E. Galan. 1998. The *Salmonella typhimurium* tyrosine phosphatase SptP is translocated into host cells and disrupts the actin cytoskeleton. *Mol. Microbiol.* **27**:359–368.
21. Galan, J. E., and Y. Fu. 2000. Modulation of actin cytoskeleton by *Salmonella* GTPase activating protein SptP. *Methods Enzymol.* **325**:496–504.
22. Galyov, E. E., S. Hakansson, A. Forsberg, and H. Wolf-Watz. 1993. A secreted protein kinase of *Yersinia pseudotuberculosis* is an indispensable virulence determinant. *Nature* **361**:730–732.
23. Galyov, E. E., S. Hakansson, and H. Wolf-Watz. 1994. Characterization of the operon encoding the YpkA Ser/Thr protein kinase and the YopJ protein of *Yersinia pseudotuberculosis*. *J. Bacteriol.* **176**:4543–4548.
24. Gemski, P., J. R. Lazere, T. Casey, and J. A. Wohlhieter. 1980. Presence of a virulence-associated plasmid in *Yersinia pseudotuberculosis*. *Infect. Immun.* **28**:1044–1047.
25. Grant, T., V. Bennett-Wood, and R. M. Robins-Browne. 1998. Identification of virulence-associated characteristics in clinical isolates of *Yersinia enterocolitica* lacking classical virulence markers. *Infect. Immun.* **66**:1113–1120.
26. Grosdent, N., I. Maridonneau-Parini, M. P. Sory, and G. R. Cornelis. 2002. Role of Yops and adhesins in resistance of *Yersinia enterocolitica* to phagocytosis. *Infect. Immun.* **70**:4165–4176.
27. Guan, K. L., and J. E. Dixon. 1990. Protein tyrosine phosphatase activity of an essential virulence determinant in *Yersinia*. *Science* **249**:553–556.
28. Hakansson, S., E. E. Galyov, R. Rosqvist, and H. Wolf-Watz. 1996. The *Yersinia* YpkA Ser/Thr kinase is translocated and subsequently targeted to the inner surface of the HeLa cell plasma membrane. *Mol. Microbiol.* **20**:593–603.
29. Hanski, C., U. Kutschka, H. P. Schmoranzler, M. Naumann, A. Stallmach, H. Hahn, H. Menge, and E. O. Riecken. 1989. Immunohistochemical and electron microscopic study of interaction of *Yersinia enterocolitica* serotype O8



- with intestinal mucosa during experimental enteritis. *Infect. Immun.* **57**:673–678.
30. **Holmstrom, A., R. Rosqvist, H. Wolf-Watz, and A. Forsberg.** 1995. Virulence plasmid-encoded YopK is essential for *Yersinia pseudotuberculosis* to cause systemic infection in mice. *Infect. Immun.* **63**:2269–2276.
  31. **Hubbert, W. T., C. W. Petenyi, L. A. Glasgow, C. T. Uyeda, and S. A. Creighton.** 1971. *Yersinia pseudotuberculosis* infection in the United States. Speticema, appendicitis, and mesenteric lymphadenitis. *Am. J. Trop. Med. Hyg.* **20**:679–684.
  32. **Iriarte, M., and G. R. Cornelis.** 1998. YopT, a new *Yersinia* Yop effector protein, affects the cytoskeleton of host cells. *Mol. Microbiol.* **29**:915–929.
  33. **Jones, M. A., M. W. Wood, P. B. Mullan, P. R. Watson, T. S. Wallis, and E. E. Galyov.** 1998. Secreted effector proteins of *Salmonella dublin* act in concert to induce enteritis. *Infect. Immun.* **66**:5799–5804.
  34. **Juris, S. J., A. E. Rudolph, D. Huddler, K. Orth, and J. E. Dixon.** 2000. A distinctive role for the *Yersinia* protein kinase: actin binding, kinase activation, and cytoskeleton disruption. *Proc. Natl. Acad. Sci. USA* **97**:9431–9436.
  35. **Lesser, C. F., and S. I. Miller.** 2001. Expression of microbial virulence proteins in *Saccharomyces cerevisiae* models mammalian infection. *EMBO J.* **20**:1840–1849.
  36. **Leung, K. Y., B. S. Reisner, and S. C. Straley.** 1990. YopM inhibits platelet aggregation and is necessary for virulence of *Yersinia pestis* in mice. *Infect. Immun.* **58**:3262–3271.
  37. **Lian, C. J., W. S. Hwang, J. K. Kelly, and C. H. Pai.** 1987. Invasiveness of *Yersinia enterocolitica* lacking the virulence plasmid: an in-vivo study. *J. Med. Microbiol.* **24**:219–226.
  38. **Marra, A., and R. R. Isberg.** 1997. Invasin-dependent and invasin-independent pathways for translocation of *Yersinia pseudotuberculosis* across the Peyer's patch intestinal epithelium. *Infect. Immun.* **65**:3412–3421.
  39. **McDonald, C., P. O. Vacratsis, J. B. Bliska, and J. E. Dixon.** 2003. The *Yersinia* virulence factor YopM forms a novel protein complex with two cellular kinases. *J. Biol. Chem.* **278**:18514–18523.
  40. **Mecenas, J., I. Bilis, and S. Falkow.** 2001. Identification of attenuated *Yersinia pseudotuberculosis* strains and characterization of an orogastric infection in BALB/c mice on day 5 postinfection by signature-tagged mutagenesis. *Infect. Immun.* **69**:2779–2787.
  41. **Mecenas, J., B. Raupach, and S. Falkow.** 1998. The *Yersinia* Yops inhibit invasion of *Listeria*, *Shigella* and *Edwardsiella* but not *Salmonella* into epithelial cells. *Mol. Microbiol.* **28**:1269–1281.
  42. **Michiels, T., P. Wattiau, R. Brasseur, J. M. Ruyschaert, and G. Cornelis.** 1990. Secretion of Yop proteins by *Yersiniae*. *Infect. Immun.* **58**:2840–2849.
  43. **Mills, S. D., A. Boland, M. P. Sory, P. van der Smissen, C. Kerbourch, B. B. Finlay, and G. R. Cornelis.** 1997. *Yersinia enterocolitica* induces apoptosis in macrophages by a process requiring functional type III secretion and translocation mechanisms and involving YopP, presumably acting as an effector protein. *Proc. Natl. Acad. Sci. USA* **94**:12638–12643.
  44. **Monack, D. M., J. Mecenas, D. Bouley, and S. Falkow.** 1998. *Yersinia*-induced apoptosis in vivo aids in the establishment of a systemic infection of mice. *J. Exp. Med.* **188**:2127–2137.
  45. **Monack, D. M., J. Mecenas, N. Ghorri, and S. Falkow.** 1997. *Yersinia* signals macrophages to undergo apoptosis and YopJ is necessary for this cell death. *Proc. Natl. Acad. Sci. USA* **94**:10385–10390.
  46. **Mulder, B., T. Michiels, M. Simonet, M. P. Sory, and G. Cornelis.** 1989. Identification of additional virulence determinants on the pYV plasmid of *Yersinia enterocolitica* W227. *Infect. Immun.* **57**:2534–2541.
  47. **Murray, R. A., and C. A. Lee.** 2000. Invasion genes are not required for *Salmonella enterica* serovar typhimurium to breach the intestinal epithelium: evidence that *Salmonella* pathogenicity island 1 has alternative functions during infection. *Infect. Immun.* **68**:5050–5055.
  48. **Nordfelth, R., and H. Wolf-Watz.** 2001. YopB of *Yersinia enterocolitica* is essential for YopE translocation. *Infect. Immun.* **69**:3516–3518.
  49. **Paff, J. R., D. A. Triplett, and T. N. Saari.** 1976. Clinical and laboratory aspects of *Yersinia pseudotuberculosis* infections, with a report of two cases. *Am. J. Clin. Pathol.* **66**:101–110.
  50. **Persson, C., N. Carballeira, H. Wolf-Watz, and M. Fallman.** 1997. The PTPase YopH inhibits uptake of *Yersinia*, tyrosine phosphorylation of p130Cas and FAK, and the associated accumulation of these proteins in peripheral focal adhesions. *EMBO J.* **16**:2307–2318.
  51. **Persson, C., R. Nordfelth, K. Andersson, A. Forsberg, H. Wolf-Watz, and M. Fallman.** 1999. Localization of the *Yersinia* PTPase to focal complexes is an important virulence mechanism. *Mol. Microbiol.* **33**:828–838.
  52. **Portnoy, D. A., and S. Falkow.** 1981. Virulence-associated plasmids from *Yersinia enterocolitica* and *Yersinia pestis*. *J. Bacteriol.* **148**:877–883.
  53. **Portnoy, D. A., S. L. Moseley, and S. Falkow.** 1981. Characterization of plasmids and plasmid-associated determinants of *Yersinia enterocolitica* pathogenesis. *Infect. Immun.* **31**:775–782.
  54. **Riley, G., and S. Toma.** 1989. Detection of pathogenic *Yersinia enterocolitica* by using Congo red-magnesium oxalate agar medium. *J. Clin. Microbiol.* **27**:213–214.
  55. **Rosqvist, R., I. Bolin, and H. Wolf-Watz.** 1988. Inhibition of phagocytosis in *Yersinia pseudotuberculosis*: a virulence plasmid-encoded ability involving the Yop2b protein. *Infect. Immun.* **56**:2139–2143.
  56. **Rosqvist, R., A. Forsberg, M. Rimpilainen, T. Bergman, and H. Wolf-Watz.** 1990. The cytotoxic protein YopE of *Yersinia* obstructs the primary host defence. *Mol. Microbiol.* **4**:657–667.
  57. **Rosqvist, R., A. Forsberg, and H. Wolf-Watz.** 1991. Intracellular targeting of the *Yersinia* YopE cytotoxin in mammalian cells induces actin microfilament disruption. *Infect. Immun.* **59**:4562–4569.
  58. **Rosqvist, R., K. E. Magnusson, and H. Wolf-Watz.** 1994. Target cell contact triggers expression and polarized transfer of *Yersinia* YopE cytotoxin into mammalian cells. *EMBO J.* **13**:964–972.
  59. **Ruckdeschel, K., A. Roggenkamp, V. Lafont, P. Mangeat, J. Heesemann, and B. Rouot.** 1997. Interaction of *Yersinia enterocolitica* with macrophages leads to macrophage cell death through apoptosis. *Infect. Immun.* **65**:4813–4821.
  60. **Sato, K.** 1987. *Yersinia pseudotuberculosis* infection in children. Clinical manifestations and epidemiology. *Contrib. Microbiol. Immunol.* **9**:111–116.
  61. **Sauvonnnet, N., I. Lambermont, P. van der Bruggen, and G. R. Cornelis.** 2002. YopH prevents monocyte chemoattractant protein 1 expression in macrophages and T-cell proliferation through inactivation of the phosphatidylinositol 3-kinase pathway. *Mol. Microbiol.* **45**:805–815.
  62. **Schulte, R., S. Kerneis, S. Klinke, H. Bartels, S. Preger, J. P. Kraehenbuhl, E. Pringault, and I. B. Autenrieth.** 2000. Translocation of *Yersinia enterocolitica* across reconstituted intestinal epithelial monolayers is triggered by *Yersinia* invasin binding to beta1 integrins apically expressed on M-like cells. *Cell. Microbiol.* **2**:173–185.
  63. **Simonet, M., S. Richard, and P. Berche.** 1990. Electron microscopic evidence for in vivo extracellular localization of *Yersinia pseudotuberculosis* harboring the pYV plasmid. *Infect. Immun.* **58**:841–845.
  64. **Skrzypek, E., C. Cowan, and S. C. Straley.** 1998. Targeting of the *Yersinia pestis* YopM protein into HeLa cells and intracellular trafficking to the nucleus. *Mol. Microbiol.* **30**:1051–1065.
  65. **Straley, S. C., and M. L. Cibull.** 1989. Differential clearance and host-pathogen interactions of YopE<sup>-</sup> and YopK<sup>-</sup> YopL<sup>-</sup> *Yersinia pestis* in BALB/c mice. *Infect. Immun.* **57**:1200–1210.
  66. **Tsolis, R. M., L. G. Adams, T. A. Ficht, and A. J. Baumler.** 1999. Contribution of *Salmonella typhimurium* virulence factors to diarrheal disease in calves. *Infect. Immun.* **67**:4879–4885.
  67. **Tsolis, R. M., L. G. Adams, M. J. Hantman, C. A. Scherer, T. Kimbrough, R. A. Kingsley, T. A. Ficht, S. I. Miller, and A. J. Baumler.** 2000. SspA is required for lethal *Salmonella enterica* serovar Typhimurium infections in calves but is not essential for diarrhea. *Infect. Immun.* **68**:3158–3163.
  68. **Viboud, G. I., and J. B. Bliska.** 2001. A bacterial type III secretion system inhibits actin polymerization to prevent pore formation in host cell membranes. *EMBO J.* **20**:5373–5382.
  69. **Von Pawel-Rammingen, U., M. V. Telepnev, G. Schmidt, K. Aktories, H. Wolf-Watz, and R. Rosqvist.** 2000. GAP activity of the *Yersinia* YopE cytotoxin specifically targets the Rho pathway: a mechanism for disruption of actin microfilament structure. *Mol. Microbiol.* **36**:737–748.
  70. **Williams, A. W., and S. C. Straley.** 1998. YopD of *Yersinia pestis* plays a role in negative regulation of the low-calcium response in addition to its role in translocation of Yops. *J. Bacteriol.* **180**:350–358.
  71. **Yao, T., J. Mecenas, J. I. Healy, S. Falkow, and Y. Chien.** 1999. Suppression of T and B lymphocyte activation by a *Yersinia pseudotuberculosis* virulence factor, yopH. *J. Exp. Med.* **190**:1343–1350.
  72. **Zhang, S., R. L. Santos, R. M. Tsolis, S. Stender, W.-D. Hardt, A. J. Baumler, and L. G. Adams.** 2002. The *Salmonella enterica* serotype typhimurium effector proteins SipA, SopA, SopB, SopD, and SopE2 act in concert to induce diarrhea in calves. *Infect. Immun.* **70**:3843–3855.
  73. **Zhang, Z. Y., J. C. Clemens, H. L. Schubert, J. A. Stuckey, M. W. Fischer, D. M. Hume, M. A. Saper, and J. E. Dixon.** 1992. Expression, purification, and physicochemical characterization of a recombinant *Yersinia* protein tyrosine phosphatase. *J. Biol. Chem.* **267**:23759–23766.
  74. **Zumbihl, R., M. Aepfelbacher, A. Andor, C. A. Jacobi, K. Ruckdeschel, B. Rouot, and J. Heesemann.** 1999. The cytotoxin YopT of *Yersinia enterocolitica* induces modification and cellular redistribution of the small GTP-binding protein RhoA. *J. Biol. Chem.* **274**:29289–29293.